Mithra and Orifarm Sign LSA for Vaginal Contraception Ring in Denmark

  • Mithra grants exclusive license for vaginal contraception ring to Orifarm for commercialization in Denmark/li>
  • Agreement follows MyringTM licenses closed with Mayne Pharma, Gynial, Adamed and Alvogen for the US, Austria, the Czech Republic and Russia, respectively
  • Vaginal ring shall be manufactured at Mithra CDMO

Liège, Belgium, 21 June 2018 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces an exclusive license and supply agreement (LSA) with Orifarm for the commercialization in Denmark of Mithra’s contraceptive vaginal ring product candidate made of ethylene vinyl acetate copolymers (EVA).

Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

Liège, Belgium, 8 June 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today presents its Phase IIb results for Donesta® at the International Menopause Society’s 16th World Congress on menopause (Vancouver, Canada).

Donesta® is Mithra’s next-generation hormone therapy (HT) product candidate with oral administration of Estetrol (E4) for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women. Mithra recently announced positive top-line results, showing a significant improvement on the frequency and severity of hot flushes, as well as on secondary menopausal symptoms such as VVA, while indicating a beneficial safety profile.

 

Information on the total number of voting rights (denominator)

Liège, Belgium, 05 June 2018 [5:45 pm CET] – Regulated information – In accordance with article 15 of the Act of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 2,672,414 new shares on 4 June 2018 in the framework of the private placement announced by press release of 30 May 2018:

Mithra Signs Binding Heads of Terms for Commercialization of Estelle® in South Korea with Women’s Health Specialist Hyundai pharm

  • Mithra eligible for milestone payments, recurring revenues and further sales-related royalty payments, with production of Estelle® for the South Korean market at the Mithra CDMO
  • With Estelle®, Hyundai Pharm aims to further expand its growing footprint in Women’s Health

Liège, Belgium, 5 June 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announced that it has signed a binding Heads of Terms agreement with Hyundai Pharm, a South Korean Women’s Health leader, for an exclusive license to commercialize Estelle® in South Korea. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate currently in pivotal Phase III trials in Europe and Russia as well as in the US and Canada, with top line results expected in Q3 2018 and Q1 2019, respectively.